Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 255Breast Neoplasms 172Neoplasms 167Colorectal Neoplasms 154Neoplasm Metastasis 127Melanoma 119Recurrence 116Prostatic Neoplasms 116Leukemia, Myeloid, Acute 115Pancreatic Neoplasms 113Ovarian Neoplasms 110Multiple Myeloma 103Lung Neoplasms 95Stomach Neoplasms 89Squamous Cell Carcinoma of Head and Neck 83Triple Negative Breast Neoplasms 81Glioblastoma 81Lymphoma 77Lymphoma, Non-Hodgkin 75Lymphoma, Large B-Cell, Diffuse 64Carcinoma, Renal Cell 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 62Advanced Solid Tumor 59Endometrial Neoplasms 58Carcinoma, Hepatocellular 57Small Cell Lung Carcinoma 54Sarcoma 52Uterine Cervical Neoplasms 51Myelodysplastic Syndromes 51Leukemia 49

Interventions

Vorinostat 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Anemia, Refractory × 1 year × Clear all
NCT00392353 2026-04-13

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
135 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡